Inventiva S.A. (EPA:IVA)
France · Delayed Price · Currency is EUR | Market Cap | 808.08M +119.6% |
| Revenue (ttm) | 6.76M -52.0% |
| Net Income | -354.14M |
| EPS | -1.90 |
| Shares Out | 236.28M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 316,989 |
| Open | 3.280 |
| Previous Close | 3.275 |
| Day's Range | 3.280 - 3.480 |
| 52-Week Range | 2.615 - 6.200 |
| Beta | 0.89 |
| Analysts | Strong Buy |
| Price Target | 9.63 (+181.58%) |
| Earnings Date | Sep 25, 2026 |
About Inventiva
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a novel peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. The company also develops TGF-β, a pre-clinical program for the tr... [Read more]
Financial Performance
In 2025, Inventiva's revenue was 6.76 million, a decrease of -52.03% compared to the previous year's 14.10 million. Losses were -354.14 million, 92.2% more than in 2024.
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for IVA stock is "Strong Buy." The 12-month stock price target is €9.63, which is an increase of 181.58% from the latest price.
News
Results of the Votes of the Combined Shareholders' General Meeting of June 30, 2026
Daix (France), New York City (New York, United States), July 2, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on...
Claret Capital Partners participates in €130m financing for Inventiva
Claret Capital Partners is providing growth funding of €43m as part of Inventiva's €130m debt financing, to support its lead asset through Phase 3.
Claret Capital Partners participates in €130m financing for Inventiva to support Phase 3 development
Claret Capital Partners is providing growth funding of €43m as part of Inventiva's €130m debt financing, to support its lead asset through Phase 3.
Inventiva announces Repayment of EIB Loans, Repurchase of a portion of EIB Warrants and the Issuance of the first two tranches under New Debt Financing
Daix (France), New York City (New York, United States), June 12, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on...
Combined General Meeting of June 30, 2026 - Availability of the Preparatory Documents
Daix (France), New York City (New York, United States), June 9,2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on t...
Inventiva Transcript: Jefferies Global Healthcare Conference 2026
A recapitalized, single-asset company is advancing lanifibranor for F2/F3 MASH, with phase III top-line data expected in Q4 2024 and a commercial launch targeted for 2028. The product is positioned to compete strongly in diabetic and fibrosis-driven segments.
Inventia Resumes Trading Of Ordinary Shares On Euronext Paris
(RTTNews) - Inventiva S.A. (Euronext Paris and Nasdaq: IVA) announced that trading of its ordinary shares on Euronext Paris resumed at approximately 3:30 p.m. CEST (9:30 a.m. ET) on June 2, 2026, foll...
Inventiva Announces Trading Resumption of its Ordinary Shares on Euronext Paris
Daix (France), New York City (New York, United States), June 2, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on...
Inventiva Announces a Comprehensive Capital Structure Optimization including Debt and Equity Financing in Advance of the Anticipated Phase 3 Readout
Daix (France), New York City (New York, United States), June 2, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on ...
Inventiva files automatic mixed securities shelf
06:12 EDT Inventiva (IVA) files automatic mixed securities shelf
Inventia Temporarily Halts Euronext Paris Trading Ahead Of Financing Transaction
(RTTNews) - Inventiva S.A. (Euronext Paris and Nasdaq: IVA) a clinical-stage biopharmaceutical company focused on therapies for metabolic dysfunction-associated steatohepatitis (MASH), announced that ...
Inventiva Announces Temporary Trading Halt of its Ordinary Shares on Euronext Paris
Daix (France), New York City (New York, United States), June 2, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on...
Inventiva Reports 2026 First Quarter Financial Information¹
Daix (France), New York City (New York, United States), May 26, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on ...
Inventiva Earnings release: Q1 2026
Inventiva released its Q1 2026 earnings on May 25, 2026, summarizing the period's financial results.
Inventiva Earnings release: Q1 2026
Inventiva released its Q1 2026 earnings on May 25, 2026, summarizing the period's financial results.
Inventiva to Present at 2026 Jefferies Global Healthcare Conference
Daix (France), New York (United States), May 21, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development...
Inventiva to Present Abstracts at the EASL Congress 2026
Daix (France), New York City (New York, United States) , May 13, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused ...
Inventiva CFO Jean Volatier to switch roles, Axel-Sven Malkomes to succeed
Inventiva (IVA) announced three new members of its leadership team: Axel-Sven Malkomes as CFO, Susan Coles as chief legal officer, and Pamela Herbster as chief people officer. Former CFO Jean…
Inventiva Strengthens Leadership Team Ahead of Expected Phase 3 Data Readout of Lanifibranor
Recruitment of Chief Financial Officer, Chief Legal Officer, and Chief People Officer reflects Inventiva's organizational build-out as it advances toward potential commercialization. Axel-Sven Malkome...
Inventiva announces filing of its 2025 Universal Registration Document and 2025 Annual Report on Form 20-F
Daix (France), New York City (New York, United States), April 8, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the developme...
Inventiva price target lowered to $15 from $17 at Stifel
Stifel lowered the firm’s price target on Inventiva (IVA) to $15 from $17 and keeps a Buy rating on the shares. The firm notes the company is in final stretches…
Inventiva Earnings Call Transcript: Q4 2025
Inventiva completed NATiV3 phase III enrollment for lanifibranor in MASH, expects top-line data in Q4 2026, and is well-funded through key milestones. Strategic focus, leadership expansion, and divestment of odiparcil position the company for regulatory and commercial readiness.
Inventiva Annual report: Q4 2025
Inventiva has published its Q4 2025 annual report on March 31, 2026.
Inventiva Earnings release: Q4 2025
Inventiva released its Q4 2025 earnings on March 31, 2026, summarizing the period's financial results.
Inventiva Earnings release: Q4 2025
Inventiva released its Q4 2025 earnings on March 31, 2026, summarizing the period's financial results.